Metabolic Category
Survodutide
THE DUAL ACTION
BI 456906
Survodutide is a dual agonist that activates both GLP-1 and glucagon receptors. This dual action may provide superior weight loss compared to GLP-1-only drugs like Semaglutide, while also improving liver health and metabolic markers. It's currently in late-stage clinical trials for both obesity and fatty liver disease.
Survodutide Evidence Snapshot
How these guides are reviewed- Regulatory status
- Not FDA approved · research use only
- Dosing guidance
- Reviewed by our clinical team
- Linked evidence
- 2 research sources
- Content updated
- Sep 15, 2026
Dose and schedule recommendations shown below come from The Peptide App Clinical Team. Research links are provided so readers can inspect the supporting evidence directly. Review the sources.
Quick Answers About Survodutide
Is Survodutide FDA approved?
No. This profile records Survodutide as not FDA approved and for research use only.
More context
Review the regulatory and source details on this page for the current context.
What dose does The Peptide App Clinical Team recommend for Survodutide?
Dose: Studied route and cadence: SubQ once weekly, with protocol-specific dose escalation.
More context
Schedule: weekly. Cycle: Follow the selected study protocol; do not infer an indefinite course.. This is clinical-team guidance for reference and does not replace individualized instructions from a licensed clinician.
What research supports this Survodutide guide?
This guide links to 2 curated or current research sources.
More context
Inspect the research section and the citations beneath the research answers for their supporting sources.
Review the Survodutide research sourcesWhat are the side effects of Survodutide?
Reported side effects of Survodutide include Nausea, Vomiting, Diarrhea, and Decreased appetite.
More context
They are reported or occasional reactions, not a prediction of what any one person will experience.
Is Survodutide safe?
Survodutide has an editorial safety grade of B (Clinical Trials).
More context
Currently in Phase 3 trials with promising safety data so far. Safety depends on dose, sourcing, health history and medical supervision, so this page does not call it safe for personal use.
What did animal studies find about survodutide and liver glucagon receptor activation?
In an animal study, survodutide reduced liver weight and lowered plasma amino acid levels, including alanine. The authors interpreted these changes as confirming that survodutide activates glucagon receptors in the liver. The reported liver findings were lower liver weight and lower plasma amino acids, with glucagon receptor activation being the authors' reading of them.
BI 456906 research background
Survodutide appears in the discovery literature under the research code BI 456906. A 2022 paper from Boehringer Ingelheim researchers describes an acylated peptide containing a C18 fatty-acid group. The research program used laboratory assays for both the glucagon receptor and the GLP-1 receptor to characterize the molecule.
[BI 456906 discovery paper, 2022](https://pmc.ncbi.nlm.nih.gov/articles/PMC9679702/)
Who is this for
Those seeking maximum weight loss potential · People with fatty liver disease (NASH/MAFLD) · Individuals who plateau on single-agonist GLP-1s · Early adopters of next-gen metabolic therapies
Market evidence
Survodutide product testing and COAs
We have not assessed certificate coverage for Survodutide yet. Research on this page describes the molecule. Vendor certificates concern particular market samples or batches; they do not change the research evidence or establish clinical safety, sterility, or suitability for use.
Survodutide research
The clinic network
Want a clinician's view on Survodutide?
Request a free connection to a peptide clinic, by telehealth or in person. A licensed clinician decides whether any treatment is right for you. What peptide therapy involves
Related Peptides
Liraglutide
THE DAILYAHighWeight Loss · Metabolic HealthMetabolic · Weight LossDose0.6 mg▲↻CycleContinuous use with medical supervision◷Kicks inSee guideFDA-approved GLP-1 for weight loss and blood sugar control with daily dosing.
Full profileNº 003 / 006Adipotide
THE FAT BURNERCModerateWeight Loss · Fat LossMetabolic · Weight LossDoseSee guide↻CycleNo established SubQ dosing cycle.◷Kicks inSee guideTargets and destroys fat cells by cutting off their blood supply.
from $7.30/mg · 26 vendorsNº 001 / 006MOTS-c
THE METABOLIC MESSENGERBGoodMetabolic Modulator · Mitochondrial SupportMetabolic · Metabolic ModulatorDose5 mg↻Cycle8-12 weeks on, 4 weeks off◷Kicks inMetabolic improvements may be measurable...Exercise in a peptide. Boost metabolism without the treadmill
from $1.20/mg · 300 vendorsNº 004 / 006Selank
THE ANXIETY REDUCERAHighNootropic · Anxiety ManagementCognitive · NootropicDose400 mcg↻Cycle6 weeks on, 6 weeks off◷Kicks inAnti-anxiety effects often noticed within...Calms anxiety while improving focus and cognitive function for balanced mood.
from $1.80/mg · 204 vendorsNº 005 / 006BPC-157
THE HEALERAHighAccelerated Healing · Neurological SupportHealing · Accelerated HealingDose250 mcg↻Cycle4-8 weeks on, then equal break◷Kicks inRecovery improvements often noticed within...Accelerates healing of tendons, ligaments, gut, and muscles throughout your body.
from $1/mg · 320 vendorsNº 002 / 006Thymosin Alpha-1
THE IMMUNE SUPERCHARGERAHighAccelerated Healing · Anti-InflammatoryHealing · Accelerated HealingDose1 mg↻CycleNo clinically established cycle for this...◷Kicks inImmune enhancement often measurable within...Strengthens immunity by maturing T-cells, used for infections and cancer support
from $3.20/mg · 150 vendorsNº 006 / 006